EMEA-001284-PIP01-12
Key facts
| Active substance |
Tivantinib
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0149/2012
|
| PIP number |
EMEA-001284-PIP01-12
|
| Pharmaceutical form(s) |
Tablet
|
| Condition(s) / indication(s) |
Treatment of hepatoblastoma
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Daiichi Sankyo Development Limited
|
| Decision type |
RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s)
|